ATE230597T1 - Verwendung einer zusammensetzung aus h+, k+ - atpase-inhibitoren und glucocortikoiden zur behandlung von nasenpolypen - Google Patents

Verwendung einer zusammensetzung aus h+, k+ - atpase-inhibitoren und glucocortikoiden zur behandlung von nasenpolypen

Info

Publication number
ATE230597T1
ATE230597T1 AT97945135T AT97945135T ATE230597T1 AT E230597 T1 ATE230597 T1 AT E230597T1 AT 97945135 T AT97945135 T AT 97945135T AT 97945135 T AT97945135 T AT 97945135T AT E230597 T1 ATE230597 T1 AT E230597T1
Authority
AT
Austria
Prior art keywords
glucocorticoids
treatment
composition
nasal polyps
atpase inhibitors
Prior art date
Application number
AT97945135T
Other languages
English (en)
Inventor
Per Lindberg
Joan Pinas-Masso
Jordi Serra-Carreras
Jan Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE230597T1 publication Critical patent/ATE230597T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
AT97945135T 1996-10-11 1997-10-01 Verwendung einer zusammensetzung aus h+, k+ - atpase-inhibitoren und glucocortikoiden zur behandlung von nasenpolypen ATE230597T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9603725A SE9603725D0 (sv) 1996-10-11 1996-10-11 New teatment
PCT/SE1997/001651 WO1998016228A1 (en) 1996-10-11 1997-10-01 USE OF AN H+, K+-ATPase INHIBITOR IN THE TREATMENT OF NASAL POLYPS

Publications (1)

Publication Number Publication Date
ATE230597T1 true ATE230597T1 (de) 2003-01-15

Family

ID=20404214

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97945135T ATE230597T1 (de) 1996-10-11 1997-10-01 Verwendung einer zusammensetzung aus h+, k+ - atpase-inhibitoren und glucocortikoiden zur behandlung von nasenpolypen

Country Status (34)

Country Link
EP (1) EP0946175B1 (de)
JP (1) JP4100713B2 (de)
KR (1) KR100510812B1 (de)
CN (1) CN1146416C (de)
AR (1) AR008886A1 (de)
AT (1) ATE230597T1 (de)
AU (1) AU738310B2 (de)
BR (1) BR9711896A (de)
CA (1) CA2268305C (de)
CZ (1) CZ298799B6 (de)
DE (1) DE69718347T2 (de)
DK (1) DK0946175T3 (de)
EE (1) EE04043B1 (de)
ES (1) ES2188995T3 (de)
HK (1) HK1022848A1 (de)
HU (1) HUP0000036A3 (de)
ID (1) ID23692A (de)
IL (1) IL129324A0 (de)
IS (1) IS1930B (de)
MY (1) MY117918A (de)
NO (1) NO321007B1 (de)
NZ (1) NZ334786A (de)
PL (1) PL190902B1 (de)
PT (1) PT946175E (de)
RS (1) RS49599B (de)
RU (1) RU2197966C2 (de)
SA (1) SA97180641B1 (de)
SE (1) SE9603725D0 (de)
SK (1) SK284252B6 (de)
TR (1) TR199900770T2 (de)
TW (1) TW568784B (de)
UA (1) UA59374C2 (de)
WO (1) WO1998016228A1 (de)
ZA (1) ZA978842B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
RS50273B (sr) 1998-08-18 2009-07-15 The Regents Of The Univeristy Of California, Antagonisti receptora epidermalnog faktora rasta za lečenje hipersekrecije mukusa u plućima
JP4543553B2 (ja) * 1999-03-03 2010-09-15 オプティノーズ アズ 鼻用の送り込み装置
EP1453493A2 (de) * 2001-11-19 2004-09-08 ALTANA Pharma AG Reversibele protonpumpen-hemmer zur behandlung von atemwegserkrankungen
US20050131026A1 (en) * 2002-03-14 2005-06-16 Atlanta Pharma Ag Use of proton pump inhibitors for the treatment of airway disorders
US20050165041A1 (en) * 2002-05-07 2005-07-28 Altana Pharma Ag Combination for the treatment of airway disorders
AU2003227710A1 (en) * 2002-05-07 2003-11-11 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
JP4755495B2 (ja) 2002-12-12 2011-08-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 組合せ医薬品
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005025578A1 (en) 2003-09-16 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN104408249B (zh) * 2014-11-24 2017-09-26 广州供电局有限公司 单芯电缆导体热性参数的确定方法及系统
KR101974504B1 (ko) * 2017-04-10 2019-05-03 재단법인 아산사회복지재단 호산구성 비용종 동물모델

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate

Also Published As

Publication number Publication date
PT946175E (pt) 2003-04-30
CN1232397A (zh) 1999-10-20
NZ334786A (en) 2000-12-22
TR199900770T2 (xx) 1999-06-21
DE69718347T2 (de) 2003-08-28
YU16399A (sh) 2000-03-21
EE9900118A (et) 1999-10-15
HUP0000036A2 (hu) 2002-05-29
ZA978842B (en) 1998-04-14
SK284252B6 (sk) 2004-12-01
DE69718347D1 (de) 2003-02-13
ID23692A (id) 2000-05-11
BR9711896A (pt) 1999-08-24
IS1930B (is) 2004-05-18
JP2001508034A (ja) 2001-06-19
RU2197966C2 (ru) 2003-02-10
HUP0000036A3 (en) 2003-02-28
SK38499A3 (en) 2000-03-13
CZ122999A3 (cs) 1999-09-15
RS49599B (sr) 2007-06-04
PL190902B1 (pl) 2006-02-28
KR100510812B1 (ko) 2005-08-31
KR20000049046A (ko) 2000-07-25
EP0946175B1 (de) 2003-01-08
CA2268305C (en) 2006-11-28
PL332692A1 (en) 1999-09-27
IS5021A (is) 1999-04-08
HK1022848A1 (en) 2000-08-25
AR008886A1 (es) 2000-02-23
MY117918A (en) 2004-08-30
SA97180641B1 (ar) 2005-12-18
DK0946175T3 (da) 2003-03-17
CZ298799B6 (cs) 2008-02-06
EE04043B1 (et) 2003-06-16
NO321007B1 (no) 2006-02-27
CA2268305A1 (en) 1998-04-23
NO991619D0 (no) 1999-04-06
AU4640997A (en) 1998-05-11
UA59374C2 (uk) 2003-09-15
HU0000036D0 (de) 2002-05-29
AU738310B2 (en) 2001-09-13
NO991619L (no) 1999-04-06
SE9603725D0 (sv) 1996-10-11
TW568784B (en) 2004-01-01
EP0946175A1 (de) 1999-10-06
JP4100713B2 (ja) 2008-06-11
CN1146416C (zh) 2004-04-21
WO1998016228A1 (en) 1998-04-23
IL129324A0 (en) 2000-02-17
ES2188995T3 (es) 2003-07-01

Similar Documents

Publication Publication Date Title
ATE230597T1 (de) Verwendung einer zusammensetzung aus h+, k+ - atpase-inhibitoren und glucocortikoiden zur behandlung von nasenpolypen
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE60143061D1 (de) Verwendung von Botulinum Toxin zur Behandlung von Gelenkschmerzen
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69720463D1 (de) Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen
DE69835031D1 (de) Neue anti-hiv immunogene (toxoide), herstellungsverfahren und verwendungen zur behandlung und vorbeugung von aids
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE69833645D1 (de) Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE204705T1 (de) Pflaster zur behandlung von pflanzen
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE69940971D1 (de) Verwendung von erythropoietin zur behandlung von primärer hämochromatosen
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0946175

Country of ref document: EP

REN Ceased due to non-payment of the annual fee